A multicenter phase III comparison of docetaxel + prednisone and mitoxantrone + prednisone in patients with hormone-refractory prostate cancer

Reviewer: S. Jack Wei, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 7 de junio del 2004

Translation for this article does not exist

Blogs

The Power of a Cancer Support Group
by Bob Riter
May 26, 2016

Frequently Asked Questions